



SVF-001 immunotherapy against chronic hepatitis D presented as late breaker at the HepDart scientific meeting

Stockholm, Sweden – December 11, 2025

SVF Vaccines AB, a biotechnology company developing next-generation vaccines and immunotherapies, today announced that new preclinical data for its SVF-001 program for chronic hepatitis B (HBV) and D (HDV) virus infections were presented as a late-breaking abstract at the HepDart scientific meeting on December 7-11 in Honolulu, Hawaii. The presentation was given by one of SVF's founders, Professor Matti Sällberg.

In the pre-clinical study, antibodies from SVF-001-immunized mice were administered to mice with humanized livers and chronic HBV/HDV coinfection. As previously reported, the antibody treatment demonstrated clear antiviral activity, resulting in reductions of blood HDV RNA levels. In this follow-up analysis, the treated mice were studied for six weeks after the end of treatment. The data show that the HDV RNA reductions lasted for up to six weeks after the end of the 4-week treatment period, demonstrating that the antibodies have an extended antiviral effect.

These data support SVF Vaccines' goal for SVF-001 to achieve strong and durable immunological control of HBV and HDV infections and ultimately deliver a functional cure for patients with chronic coinfection.

"The late-breaker presentation in Honolulu is an important external recognition of our work," says John Öhd, Chairman of the Board of SVF Vaccines AB. "The durable antiviral effect we see in this preclinical model supports the therapeutic potential of SVF-001, offering patients the hope of a new immunotherapy that will stably control chronic HBV and HDV."

For further information, please contact:

John Öhd, Chairman of the Board, SVF Vaccines AB

Phone: +46 (0) 70 766 80 97, e-mail: john.ohd@karolinskadevelopment.com

About SVF Vaccines

SVF Vaccines AB is a Swedish biotechnology company developing next-generation DNA vaccines and immunotherapies based on proprietary technology originating from Karolinska Institutet. The company's portfolio includes SVF-001, a therapeutic immunotherapy for chronic hepatitis B and D, and SVF-002, a universal prophylactic vaccine against COVID-19, as well as early-stage discovery programs for other serious infectious diseases.